The Ups and Downs of Biosimilar Development
ArticlesDrug Discovery and DevelopmentPodcasts

The Ups and Downs of Biosimilar Development

In this podcast, biosimilar key opinion leader Dr. Paul Rhyne provides an overview of the current state of biosimilars and their global impact. Leveraging his 20+ years of experience in developing biologics, he discusses how cost and patient access play a big role in this new field of research.
READ MORE →
Biosimilars: Providing More Treatment Options
ArticlesDrug Discovery and DevelopmentGeneral Interest

Biosimilars: Providing More Treatment Options

It is hoped that the development of biosimilars will lead to more accessible and cost-effective treatment options. Here we explore the current opportunities for biosimilars in rheumatoid arthritis and discuss the opportunities and concerns tied to their use.
READ MORE →
What's New in U.S. Biosimilar-Land?
ArticlesDrug Discovery and DevelopmentFeatured StoriesGeneral Interest

What’s New in U.S. Biosimilar-Land?

Biosimilars are gaining in popularity and estimates predict that the U.S. could save between $40–250 billion in healthcare costs over the next decade by switching from biologics to biosimilars. See how biosimilars have gained in popularity recently, the challenges the U.S. faces in developing them, and what the future holds.
READ MORE →
The Importance of In Vitro Assays in the Development of Biosimilars
ArticlesDrug Discovery and DevelopmentGeneral InterestPodcasts

The Importance of In Vitro Assays in the Development of Biosimilars

In this podcast, biosimilar expert, Amanda Turner, provides an in-depth explanation of the various in vitro assays used in biosimilar development and the importance of choosing the right assay type and components to achieve success.
READ MORE →
ArticlesDrug Discovery and DevelopmentFeatured StoriesGeneral Interest

Biosimilars. Are They Ready for Primetime?

Is the hype surrounding biosimilars real or simply a hopeful view on an exceedingly expensive drug market? Read this article to find out more about biosimilars and understand the challenges facing the biosimilars industry.
READ MORE →